Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-licensure effectiveness of bivalent HPV vaccine in Chinese females
CTR20210535Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus type 16 L1 capsid protein antigen in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma, human papillomavirus infection, sponsored by GSK. Started Apr 2021; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinomahuman papillomavirus infection
Beyond the preview
Go deeper on CTR20210535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210535.